Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
SAN DIEGO, Oct. 17, 2016 -- SENTÉ, a privately held specialty aesthetics company pioneering the development of differentiated medical grade skincare products based on the science of glycosaminoglycan’s, today announced that the company has received a new patent grant, Process For The Purification Of Heparan Sulfate And Use Thereof In Cosmetological And Dermatological Preparations (U.S. Patent No. 9,4330,099) by the United States Patent and Trademark Office (USPTO). The company’s patent estate has now produced patents in Europe and the United States, further strengthening its ability to distribute innovative skin care products worldwide.
“The issuance of this patent is a major milestone for the company and comes at a time when we are gaining significant traction,” said Laurent Combredet, Chief Executive Officer. “This further solidifies our IP position and adds to our vision of becoming a leading aesthetics company dedicated to pioneering glycosaminoglycan science.”
“Our focus is to remain dedicated to the development of products based on rigorous science and clinical research,” said Faheem Hasnain, Chairman of the Board of Directors. “This patent grant allows us to continue developing innovative and market disrupting technologies in the US and abroad.”
About SENTÉ:
SENTÉ is a privately held specialty aesthetics company leveraging its expertise and foundation in biotechnology to deliver novel, science-based skin care products. SENTÉ is a recognized leader in the development of innovative and targeted medical skincare products based on glycosaminoglycans. Founded in 2007 and based in San Diego, California, further information may be found at http://sentelabs.com/. SENTÉ products are available through its exclusive network of physicians and medically supervised spas.
Media Contact: Creative Media Marketing Danielle Hale [email protected] p: 212.979.8884 ext. 213
